FamiCord Group Recognized as Europe’s Leading Stem Cell Bank

Leadership in the European Stem Cell Banking Market

FamiCord is the largest stem cell bank in Europe and the third largest in the world. The quality of its services is validated by international certifications, and the company has now been recognized as Europe’s Leading Stem Cell Bank by Life Sciences Review, highlighting its commitment to excellence, clinical reliability, and innovation in stem cell banking.
FamiCord Group have been awarded as “The Europe’s Leading Stem Cell Bank” , independent experts jury underlined FamiCord has established itself as a leading provider in the field, guiding families through the collection, processing, and long-term preservation of cord blood and perinatal tissues.

Criteria Behind the Life Sciences Review Award

The “Europe’s Leading Stem Cell Bank” award is part of Life Sciences Review’s annual recognition program, which highlights companies demonstrating outstanding leadership, technological advancement, and a proven commitment to improving patient outcomes. The selection is based on life sciences expert evaluation, company track record, and the tangible impact of their work within the life sciences industry.

The award reflects FamiCord’s comprehensive system that ensures the therapeutic potential of stem cells from birth, from collection and processing to storage and eventual clinical use. Nearly half of the group’s laboratories are accredited by the AABB, and all operations comply fully with national regulations while aligning with Europe’s bone marrow transplant and cell therapy community as an EBMT member- comments Tomasz Baran, Chief Medical Officer of FamiCord Group.

Clinical Impact and Global Expansion

FamiCord’s pioneering approach extends to clinical applications, with almost 2,000 patients having benefited from perinatal stem cell therapies. The company continues its global expansion, including the opening of its first laboratory in Dubai in 2024, which has also achieved AABB accreditation.

Commitment to Innovation and Medical Collaboration

FamiCord is committed not only to advancing its infrastructure but also to being a reliable and active partner for the medical community, supporting clinical practice and research by collaborations with institutions such as the Medical University of Lublin enable families to access innovative treatments for conditions like cerebral palsy and autism, following internationally recognized clinical protocols.
The recognition by Life Sciences Review underscores FamiCord’s position as the most trusted stem cell bank in Europe, demonstrating that its services go beyond storage to provide real therapeutic options when needed. By maintaining rigorous standards and embracing clinical innovation, FamiCord ensures that every preserved sample has the potential to support life-saving and regenerative therapies for children and adults alike.

About Life Sciences Review

Life Sciences Review is a leading industry publication that recognizes innovation and excellence across biotechnology, pharmaceuticals, healthcare, and life sciences sectors. The magazine provides expert insights, analyses, and annual rankings of organizations setting benchmarks for quality, innovation, and clinical impact worldwide

References: https://www.lifesciencesrevieweurope.com/famicord